Cystic Fibrosis Foundation
205
30
37
140
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.3%
15 terminated/withdrawn out of 205 trials
90.3%
+3.8% vs industry average
11%
23 trials in Phase 3/4
42%
59 of 140 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (205)
The PROMISE Pediatric Study 6 to 11 Years Old
Role: collaborator
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
Role: collaborator
Genetic Modifiers of Cystic Fibrosis Related Diabetes
Role: collaborator
Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs
Role: collaborator
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
Role: collaborator
Colorectal Cancer Screening in Cystic Fibrosis
Role: collaborator
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
Role: collaborator
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Role: collaborator
COVID-19 ANtibody Responses in Cystic Fibrosis: CAR-CF
Role: collaborator
Bionic Pancreas in CFRD
Role: collaborator
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Role: collaborator
Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
Role: collaborator
CF Wellness Program
Role: collaborator
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Role: collaborator
Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection
Role: collaborator
Rare CFTR Mutation Cell Collection Protocol (RARE)
Role: collaborator
COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF
Role: collaborator
COVID-19 Antibody Responses in Cystic Fibrosis
Role: collaborator
Semaglutide in CFRD
Role: collaborator
Pulmonary Vascular Disease in CF
Role: collaborator